Latest news

Research & DevelopmentJuly 22, 2026

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

Summit Therapeutics and its partner Akeso have released updated overall survival data from the Phase 3 HARMONi trial, providing...

TechnologyJuly 22, 2026

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

The U.S. Food and Drug Administration (FDA) granted Johnson & Johnson De Novo clearance for the world's first table-integrated...

InsightsJuly 20, 2026

Top 10 Metrics Pharma Leaders Should Track During Digital Transformation

Executive Summary Digital transformation has become one of the pharmaceutical industry's most significant strategic priorities. Companies are investing billions in...

UncategorizedJuly 20, 2026

Sarclisa Escena Wins FDA Approval for Subcutaneous Use in Multiple Myeloma

Sanofi has received approval from the U.S. Food and Drug Administration for Sarclisa Escena, a subcutaneous formulation of its...

Research & DevelopmentJuly 20, 2026

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

The Advanced Research Projects Agency for Health (ARPA-H) has...

CommercialJuly 20, 2026

GSK views the Hansoh-partnered ADCs’ phase 3 victory in China as confirming its “priority asset.”

Hansoh Pharmaceutical's two eagerly awaited ADCs have continued to...

InsightsJuly 20, 2026

The Return of M&A as a Growth Strategy in Biopharma

Executive Summary Mergers and acquisitions (M&A) have long played a central role in shaping the global biopharmaceutical industry. For decades, pharmaceutical...

InsightsJuly 20, 2026

Top 10 Reasons Pharma Companies Are Building Internal AI Governance Teams

Executive Summary Artificial intelligence (AI) is rapidly becoming embedded across the pharmaceutical value chain. From drug discovery and clinical development...

InsightsJuly 20, 2026

Why Traditional Pharma Marketing Models Are Being Rewritten

Traditional Pharma:Executive Summary The pharmaceutical industry's commercial model is undergoing one of its most significant transformations in decades. For years, pharmaceutical...

ClinicalJuly 19, 2026

Ionis and AstraZeneca falter as the ATTR-CM medication fails Phase 3

Antisense therapeutic AstraZeneca and Ionis Pharmaceuticals drug Wainua did...

RegulatoryJuly 19, 2026

Merck Makes History By Getting FDA Green Light For Lipfendra

A decade after PCSK9 inhibitors first entered the market,...

CommercialJuly 19, 2026

Vogenx Files for a Nasdaq Capital Market IPO to Fund Metabolic Drug

Vogenx is preparing to enter the public markets by filing for a Nasdaq listing, with plans to use the...

ClinicalJuly 18, 2026

Axiom Reports Phase 1 Results for Stem Cell Therapy in Newborn Brain Injuries

Axiom Biosciences has reported results from a phase 1 clinical trial evaluating an umbilical cord-derived mesenchymal stem cell (MSC)...

CommercialJuly 16, 2026

AstraZeneca travels to China once more and purchases Dizal’s lung cancer medication for up to $1.5 billion

AstraZeneca has committed to spending up to $1.5 billion to partner with Dizal Pharmaceutical of China for an exclusive,...

Regulatory

Merck Makes History By Getting FDA Green Light For Lipfendra

A decade after PCSK9 inhibitors first entered the market,...

Editorial Team -

Commercial

GSK views the Hansoh-partnered ADCs’ phase 3 victory in China as confirming its “priority asset.”

Hansoh Pharmaceutical's two eagerly awaited ADCs have continued to...

Editorial Team -

Commercial

Sutro and Astellas enter partnership for development of immunostimulatory ADCs

Sutro Biopharm and Astellas Pharma have entered a strategic,...

Commercial

Pharma manufacturers lawsuits against payers and benefit managers preferred drugs are on FTC’s radar

The attention of federal antitrust regulators has been drawn to a slew of lawsuits filed by pharmaceutical companies, challenging the “preferred” medicine list of payers and benefit managers.